We demonstrate that dual inhibition of JAK2/STAT5 and BCR-ABL is more effective in eliminating CML LSCs, but not their healthy counterparts, than TKIs alone in vitro, and significantly enhances progression free survival in mice. Here, JAK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.